Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TULIP-1: Anifrolumab in Active SLE
NCT02446912Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by AstraZeneca. Primary endpoint: SLE Responder Index 4 at 52 weeks. Started Jun 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02446912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446912.